The Great Britain is witnessing a growing surge in interest surrounding copyright substances. Beyond the common use of psilocybin and LSD, investigators and enthusiasts are increasingly focused on less-charted territories, particularly copyright and the nascent cannabinoid, CBG. The evolving movement encompasses clinical trials into psychological w